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Despite the now significant contribution of magnetic resonance imaging (MRI), the accurate and timely 
diagnosis of multiple sclerosis (MS) is still clinically challenging. Differentiating a radiologically isolated 
syndrome from MS requires an index clinical event or progression [1], and where a symptom cannot be 
reasonably robustly attributed to white or grey matter lesions, there is the risk of making the diagnosis of MS 
that is not helpful. 
 
Alhussona et al. (this issue), with their case series, highlight the complexities of attributing paroxysmal, and 
in particular cortical, symptoms such as epileptic seizures to inflammatory demyelinating lesions, and 
establishing a diagnosis of MS based on them. Epilepsy is known to be more common in people with MS 
than the general population, but it may not be the cause of their epilepsy [2], and the risk of someone with 
epilepsy having MS appears to be very low when compared with a more typical MS presentations, such as 
transverse myelitis or optic neuritis (for example [3]). As such epilepsy per se is not a particularly MS 
specific clinical feature. Considering this the other way round, while the prevalence of cortical MS lesions 
has been linked with the likelihood of having epilepsy [4], and lesions in the temporal lobes perhaps more so 
[5, 6], this association is less clear than, for example, that of Lhermittes sign with cervical cord lesions [7]. 
As such cortical lesions per se are not a specific feature of epilepsy in MS. 
 
Making a diagnosis of MS, based on a single clinical event and MRI, essentially relies on the sensitivity and 
specificity with which MRI criteria can predict subsequent MS-related clinical events. The performance of 
MRI criteria, applied following symptoms typically associated with white matter lesions, is such that they 
can be used diagnostically [1], but it is not known if the criteria are as applicable following symptoms likely 
to be of cortical origin. As Alhussona et al. make clear, diagnosing MS requires careful consideration of all 
the evidence, not simply the application of MRI diagnostic criteria. For some presentations, such as epilepsy, 
an MS diagnosis is likely to be more tentative than for more typical MS presentations. In such situations, 
where MS-like pathology may not be the clinically relevant process, the risks of disease modifying 
treatments will need to be even more carefully weighed against their potential benefits. 
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